Legal Representation
Attorney
Eric T. Fingerhut
USPTO Deadlines
Next Deadline
909 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-02-01)
Due Date
February 01, 2028
Grace Period Ends
August 01, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Aug 1, 2022 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
Jul 13, 2022 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
Jul 13, 2022 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
May 1, 2022 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
Feb 1, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Dec 24, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Nov 23, 2021 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
Nov 16, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Nov 16, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Oct 28, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Oct 27, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Oct 27, 2021 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
Oct 27, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
Oct 13, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Oct 12, 2021 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
Oct 12, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Oct 12, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jul 9, 2021 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
Jul 9, 2021 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
Jul 9, 2021 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
Jun 10, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Mar 16, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Mar 15, 2021 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Mar 15, 2021 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Mar 15, 2021 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
Mar 15, 2021 | EWOR | I | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | Loading... |
Mar 15, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Mar 15, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Mar 15, 2021 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Mar 15, 2021 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Mar 15, 2021 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
Mar 15, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Mar 15, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Mar 15, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Mar 15, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Sep 14, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Sep 14, 2020 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
Sep 14, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jun 18, 2020 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | Loading... |
Jun 3, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
Nov 21, 2019 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
Jul 5, 2019 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
Jun 19, 2019 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
Jun 19, 2019 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
May 9, 2019 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
Oct 19, 2018 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
Oct 19, 2018 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
Oct 19, 2018 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
Oct 1, 2018 | DMCC | I | DATA MODIFICATION COMPLETED | Loading... |
Sep 28, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparations, namely, vaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, growth hormone deficiencies, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncological disorders, ophthalmologic disorders, infectious diseases, enzyme replacement therapy, anti-inflammatory diseases, pain, respiratory system disorders, autoimmune disorders, vaccines, non-alcoholic steatohepatitis, brain diseases, bone diseases, CNS diseases, myopathies, obesity, wounds healing, the hormonal system disorders, namely, growth hormone deficiencies, diabetes and angiogenesis, the ophthalmological system disorders, namely, angiogenesis, the angiogenic system disorders, the central nervous system disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system disorders, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system diseases, the metabolic system disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system disorders, namely, growth hormone deficiencies, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system disorders, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicides
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific research, conducting of tests regarding medical applications, namely, conducting clinical trials for others, packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, namely, pharmaceutical products development, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology
First Use Anywhere:
0
First Use in Commerce:
0
Class 045
Licensing of industrial property; legal services
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the turquoise word "ASCENDIS" under which is the grey word "PHARMA" next to a polygon broken by a white curved band in which the top is turquoise and the bottom is blue.
Color Claim
The color(s) turquoise, grey, white and blue is/are claimed as a feature of the mark.
Classification
International Classes
005
042
045
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMA"